Skip to content

Study · Measured the body's own peptide · 2015

2 results

Effect of Cholecalciferol Supplementation on Vitamin D Status and Cathelicidin Levels in Sepsis: A Randomized, Placebo-Controlled Trial.

Quraishi SA, De Pascale G, Needleman JS, Nakazawa H, Kaneki M, Bajwa EK, Camargo CA Jr, Bhan I

Critical care medicine1 Sept 2015Cited by 139 (Europe PMC)

PMID26086941 (opens in a new tab)PMCIDPMC4537665 (opens in a new tab)DOI10.1097/ccm.0000000000001148 (opens in a new tab)PepBankPUB-26086941
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelRandomized controlled trialOther

    In septic ICU patients, the median change in plasma LL‑37 at day 5 differed between groups: it rose with 400,000 IU cholecalciferol and fell with placebo.

    In plain wordsIn septic ICU patients, a high vitamin D dose raised the body's own LL‑37 levels, while levels fell with placebo.

    Peptide
    LL-37
    Outcome
    IncreaseChange in plasma LL-37 at day 5
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Immune response · Immune and inflammation

    Measurements

    Median change in LL-37
    −17%
    placebo
    Median change in LL-37
    4%
    200,000 IU cholecalciferol
    Median change in LL-37
    30%
    400,000 IU cholecalciferol

    Source sentences

    Summary
    LL-37: -17% (-9% to -23%), 4% (-10% to 14%), and 30% (23-48%) (p = 0.04)
    3 context sentences
    Summary · context
    Relative to baseline, on day 5, median change in biomarkers for placebo, 200,000 IU cholecalciferol, and 400,000 IU cholecalciferol groups, respectively
    Summary · context
    To compare changes in vitamin D status and cathelicidin (LL-37) levels in septic ICU patients treated with placebo versus cholecalciferol.
    Summary · context
    Placebo (n = 10) versus 200,000 IU cholecalciferol (n = 10) versus 400,000 IU cholecalciferol (n = 10), within 24 hours of new-onset severe sepsis or septic shock.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelRandomized controlled trialOther

    In septic ICU patients, bioavailable 25-hydroxyvitamin D correlated positively with the body's own LL‑37, but total 25-hydroxyvitamin D did not.

    In plain wordsIn septic ICU patients, higher bioavailable vitamin D was linked to higher natural LL‑37 levels.

    Peptide
    LL-37
    Outcome
    Not applicableCorrelation of bioavailable 25-hydroxyvitamin D with LL-37
    Study

    n = 30

    Outcome group
    Immune response · Immune and inflammation

    Measurements

    Spearman correlation
    0.44 rho
    bioavailable 25-hydroxyvitamin D vs LL-37

    Source sentences

    Summary
    A positive correlation was observed between bioavailable 25-hydroxyvitamin D and LL-37 (Spearman ρ = 0.44; p = 0.03) but not for total 25-hydroxyvitamin D and LL-37.
    2 context sentences
    Summary · context
    To compare changes in vitamin D status and cathelicidin (LL-37) levels in septic ICU patients treated with placebo versus cholecalciferol.
    Summary · context
    Placebo (n = 10) versus 200,000 IU cholecalciferol (n = 10) versus 400,000 IU cholecalciferol (n = 10), within 24 hours of new-onset severe sepsis or septic shock.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:57 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.